[go: up one dir, main page]

MA47310A - Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer - Google Patents

Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer

Info

Publication number
MA47310A
MA47310A MA047310A MA47310A MA47310A MA 47310 A MA47310 A MA 47310A MA 047310 A MA047310 A MA 047310A MA 47310 A MA47310 A MA 47310A MA 47310 A MA47310 A MA 47310A
Authority
MA
Morocco
Prior art keywords
atzolizumab
cabozantinib
combinations
cancer treatment
cancer
Prior art date
Application number
MA047310A
Other languages
English (en)
Inventor
Colin Hessel
Christian Scheffold
Gisela Schwab
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA47310A publication Critical patent/MA47310A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA047310A 2017-01-20 2018-01-19 Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer MA47310A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US201762458447P 2017-02-13 2017-02-13

Publications (1)

Publication Number Publication Date
MA47310A true MA47310A (fr) 2019-11-27

Family

ID=61569414

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047310A MA47310A (fr) 2017-01-20 2018-01-19 Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer

Country Status (15)

Country Link
US (2) US11198731B2 (fr)
EP (1) EP3570840B1 (fr)
JP (3) JP7222895B2 (fr)
KR (2) KR20230169458A (fr)
CN (4) CN117205313A (fr)
AU (2) AU2018210397B2 (fr)
BR (1) BR112019015011A2 (fr)
CA (1) CA3049452A1 (fr)
ES (1) ES3031468T3 (fr)
IL (1) IL268138B (fr)
MA (1) MA47310A (fr)
MX (2) MX389966B (fr)
UA (1) UA126970C2 (fr)
WO (1) WO2018136796A1 (fr)
ZA (1) ZA201904652B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
CN117205313A (zh) * 2017-01-20 2023-12-12 埃克塞里艾克西斯公司 治疗癌症的卡博替尼与阿特珠单抗组合
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3087578C (fr) 2018-01-18 2023-08-08 Array Biopharma Inc. Composes de pyrazolo[3,4-d]pyrimidine substitues utilises en tant qu'inhibiteurs de la kinase ret
EP3740486A1 (fr) 2018-01-18 2020-11-25 Array Biopharma, Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
EP3740491A1 (fr) 2018-01-18 2020-11-25 Array Biopharma, Inc. Composés de pyrrolo[2,3-d]pyrimidines substitués utilisés en tant qu'inhibiteurs de la kinase ret
CA3088200A1 (fr) 2018-01-26 2019-08-01 Exelixis, Inc. Composes destines au traitement de troubles dependant de la kinase
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
CA3147678A1 (fr) * 2018-09-05 2020-03-12 Solomon OKBAZGHI Formulations d'immunoglobuline a
WO2020055672A1 (fr) 2018-09-10 2020-03-19 Array Biopharma Inc. Composés hétérocycliques condensés comme inhibiteurs de kinases ret
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CA3186517A1 (fr) * 2020-07-31 2022-02-03 Exelixis, Inc. Associations pour le traitement du cancer
WO2022040555A2 (fr) * 2020-08-21 2022-02-24 Exelixis, Inc. Méthode de traitement du cancer
US20240317854A1 (en) * 2021-03-19 2024-09-26 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
WO2008083319A1 (fr) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Formes à l'état solide de l'ilaprazole de pureté énantiomérique
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
CA2758030C (fr) * 2009-01-16 2019-01-08 Exelixis, Inc. Sel de malate de n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer
TWI619495B (zh) 2010-07-16 2018-04-01 艾克塞里克斯公司 Ｃ-ｍｅｔ調節劑醫藥組合物
JP2016515628A (ja) * 2013-04-04 2016-05-30 エグゼリクシス， インコーポレイテッド 癌を治療するための複合薬
CA2939546C (fr) 2014-02-14 2023-01-17 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, procedes de preparation, et methodes d'utilisation
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CA3021445A1 (fr) * 2016-04-19 2017-10-26 Exelixis, Inc. Procede de traitement du cancer du sein negatif triple
CN117205313A (zh) * 2017-01-20 2023-12-12 埃克塞里艾克西斯公司 治疗癌症的卡博替尼与阿特珠单抗组合

Also Published As

Publication number Publication date
JP2022121594A (ja) 2022-08-19
BR112019015011A2 (pt) 2020-04-28
CN117771363A (zh) 2024-03-29
AU2018210397B2 (en) 2024-02-29
JP7222895B2 (ja) 2023-02-15
ZA201904652B (en) 2024-11-27
CN110352057A (zh) 2019-10-18
US20220056138A1 (en) 2022-02-24
CN117205313A (zh) 2023-12-12
MX2019008032A (es) 2019-12-16
NZ755494A (en) 2025-06-27
MX389966B (es) 2025-03-20
ES3031468T3 (en) 2025-07-09
AU2024203472A1 (en) 2024-06-13
EP3570840A1 (fr) 2019-11-27
MX2022001718A (es) 2022-03-11
US20190352403A1 (en) 2019-11-21
IL268138B (en) 2022-08-01
EP3570840B1 (fr) 2025-03-19
US11198731B2 (en) 2021-12-14
AU2018210397A1 (en) 2019-07-25
JP2024019720A (ja) 2024-02-09
KR102610764B1 (ko) 2023-12-07
KR20190107103A (ko) 2019-09-18
UA126970C2 (uk) 2023-03-01
CN117205312A (zh) 2023-12-12
CA3049452A1 (fr) 2018-07-26
IL268138A (en) 2019-09-26
WO2018136796A1 (fr) 2018-07-26
KR20230169458A (ko) 2023-12-15
JP2020514311A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
IL269150A (en) Compositions and methods for treating cancer
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
IL268814A (en) Compositions and methods for treatment of cancer
IL293783A (en) Compounds and compositions for treating hematological disorders
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
IL263224A (en) Methods and compositions for treating cancers
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL268872A (en) Methods and compositions for treating cancers using antisense
IL269157A (en) Compositions and methods for treating cancer
EP3672650A4 (fr) Hydrogel pour l'ingénierie tissulaire et la bio-impression
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3423048A4 (fr) Polythérapie pour le traitement du cancer de l'ovaire
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
IL262508A (en) Methods and compositions for the treatment of degenerate bone
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
EP3347010A4 (fr) Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer
EP3652195A4 (fr) Conjugué de saporine peptidique pour le traitement du cancer
EP3873205A4 (fr) Substances et méthodes pour le traitement du cancer
EP3870104A4 (fr) Méthodes et substances pour le traitement du cancer